Original Article

The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer


Background: We aimed to investigate the expression level of breast cancer susceptibility gene 2 (BRCA2) and its changes during chemotherapy in patients with different pathological types of mammary cancer (MC).

Methods: Overall, 102 patients treated in Affiliated Tumor Hospital of Guangxi Medical University, China from April 2013 to August 2017 were enrolled as experimental group, including 58 patients with noninvasive MC (group A) and 44 with invasive MC (group B). Fifty healthy volunteers at the same time were enrolled as control group. The relative expression of BRCA2 in the blood of MC patients was detected by real-time fluorescence quantitative PCR (FQ-PCR).

Results: In the experimental group, the expression level of BRCA2 in group A was higher than that in group B before chemotherapy (P<0.001); the expression level in group A and group B 1 month after chemotherapy was higher than that before chemotherapy (P<0.001); the expression level in the both groups 3 months after chemotherapy was higher than that 1 month after chemotherapy (P<0.001); the expression level of BRCA2 in blood of group A increased gradually before, 1 month and 3 months after chemotherapy (P<0.001). The expression level of BRCA2 in blood of group B increased gradually at the same time points (P<0.001).

Conclusion: BRCA2 is over-expressed in noninvasive MC patient and under-expressed in invasive MC patient. And it can be used as an index for monitoring the condition of MC patients with different pathological types during chemotherapy.



1. Zou Z, Hu J, Mccoy TP (2014). Quality of life among women with breast cancer liv-ing in Wuhan, China. Int J Nurs Sci, 1: 79-88.
2. Kim Y, Yoo KY, Goodman MT (2015). Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing fac-tors. Asian Pac J Cancer Prev, 16: 2857-70.
3. Campbell I, Scott N, Seneviratne S, Kollias J, Walters D, Taylor C, Roder D (2015). Breast cancer characteristics and survival differences between Maori, Pacific and other New Zealand women included in the Quality Audit program of Breast Sur-geons of Australia and New Zealand. Asian Pac J Cancer Prev, 16: 2465-2472.
4. Schedin P (2006). Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer, 6:281-91.
5. Lara K, Consigliere N, Pérez J, Porco A (2012). BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Bi-ol Res, 45:117-30.
6. Kasi PM, Pedersen KS, Mcwilliams RR (2015). BRCA2-associated pancreatic can-cer and current screening guidelines. Can-cer, 121: 3046.
7. Doss CGP, Nagasundaram N (2014). An Integrated in Silico Approach to Analyze the Involvement of Single Amino Acid Polymorphisms in FANCD1/BRCA2-PALB2 and FANCD1/BRCA2-RAD51 Complex. Cell Biochem Biophys, 70: 939-956.
8. Tacconi EM, Lai X, Folio C, et al (2017). BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. EMBO Mol Med, 9: 1398-1414.
9. Wen D, He Y, Wei L, et al (2016). Incidence rate of female breast cancer in urban Shi-jiazhuang in 2012 and modifiable risk fac-tors. Thorac Cancer, 7: 522-529.
10. Gradishar WJ, Anderson BO, Balassanian R, et al (2015). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2015. J Natl Compr Canc Netw, 13: 448-475.
11. Othieno-Abinya NA, Nyabola LO, Abwao HO, Ndege P (2002). Postsurgical man-agement of patients with breast cancer at Kenyatta National Hospital. East Afr Med J, 79(3) :156-62.
12. Xu J, Yang W, Wang Q, et al (2014). De-creased HCRP1 expression is associated with poor prognosis in breast cancer pa-tients. Int J Clin Exp Pathol, 7: 7915-7922.
13. Muggerud AA, Rønneberg JA, Wärnberg F, et al (2010). Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res, 12(1) :R3.
14. Wolff AC, Hammond MEH, Hicks DG, et al (2013). Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American So-ciety of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol, 31: 3997-4013.
15. Giró-Perafita A, Palomeras S, Lum D, et al (2016). Preclinical Evaluation of Fatty Ac-id Synthase and EGFR Inhibition in Tri-ple Negative Breast Cancer. Clin Cancer Res, 22: 4687-4697.
16. Zheng H, Luo RC (2005). [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer]. Di Yi Jun Yi Da Xue Xue Bao, 25(10):1293-4, 1298 [In Chinese].
17. Yip CH, Bhoo Pathy N, Teo SH (2014). A review of breast cancer research in malay-sia. Med J Malaysia, 69:8-22.
18. Norquist B, Harrell M, Walsh T, et al (2014). Germline mutations in cancer susceptibil-ity genes in brca1 and BRCA2 negative families with ovarian and breast cancer. Gynecol Oncol, 135: 383.
19. Mcallister KA, Haugen-Strano A, Hagevik S, et al (1997). Characterization of the rat and mouse homologues of the BRCA2 breast cancer susceptibility gene. Cancer Res, 57: 3121-3125.
20. Lou DI, Mcbee RM, Le UQ, et al (2014). Rapid evolution of BRCA1, and BRCA2 in humans and other primates. BMC Evol Biol, 14: 155.
21. Chodosh LA (1998). Expression of BRCA1 and BRCA2 in normal and neoplastic cells. J Mammary Gland Biol Neoplasia, 3: 389-402.
22. Shahid T, Soroka J, Kong E, et al (2014). Structure and mechanism of action of the BRCA2 breast cancer tumor suppressor. Nat Struct Mol Biol, 21: 962-968.
IssueVol 48 No 9 (2019) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v48i9.3025
Noninvasive mammary cancer Invasive mammary cancer BRCA2 Chemotherapy

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
HUANG Y, LUO M, HUANG J, HUANG S, WEI L, ZHANG Y, ZHANG Z. The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer. Iran J Public Health. 2019;48(9):1654-1662.